Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | MBOAT4 | Q96T53 | 7/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253150 | 0.92 | MBOAT4 (0.47) | RIPK1MBOAT4MMP13ENPP2KCNN4 | |
| SCHEMBL8253129 | 0.92 | RIPK1 (0.42) | RIPK1MBOAT4MMP13ENPP2KCNN4 | |
| SCHEMBL10162258 | 0.85 | RIPK1 (0.39) | RIPK1MBOAT4MMP13ENPP2KCNN4 | |
| SCHEMBL10165518 | 0.85 | MMP13 (0.60) | MMP13ADAMTS4MMP3 | |
| SCHEMBL10165604 | 0.84 | MMP13 (0.46) | MMP13PDE2A | |
| SCHEMBL10161793 | 0.82 | MMP13 (0.60) | RIPK1MBOAT4MMP13ENPP2ADAMTS4 | |
| SCHEMBL10166190 | 0.82 | SMN1; SMN2 (0.46) | MMP13 | |
| SCHEMBL8255707 | 0.80 | MMP13 (0.47) | RIPK1MBOAT4MMP13KCNN4SCN5A | |
| SCHEMBL8255825 | 0.79 | MMP13 (0.67) | RIPK1MBOAT4MMP13KCNN4ADAMTS4 | |
| SCHEMBL8256464 | 0.79 | MMP13 (0.60) | RIPK1MBOAT4MMP13SCN9AADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | RIPK1 3619/4885MBOAT4 2357/4885MMP13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.